Cargando…

Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67: Are there Patients who are less Likely to Benefit?

PURPOSE: Incomplete reperfusion after mechanical thrombectomy (MT) is associated with a poor outcome. Rescue therapy would potentially benefit some patients with an expanded treatment in cerebral ischemia score (eTICI) 2b50/2b67 reperfusion but also harbors increased risks. The relative benefits of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurmann, Christoph C., Mujanovic, Adnan, Piechowiak, Eike I., Dobrocky, Tomas, Zibold, Felix, Beyeler, Morin, Vynckier, Jan, Seiffge, David, Meinel, Thomas R., Mordasini, Pasquale, Arnold, Marcel, Fischer, Urs, Gralla, Jan, Kaesmacher, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424153/
https://www.ncbi.nlm.nih.gov/pubmed/34989817
http://dx.doi.org/10.1007/s00062-021-01131-0
_version_ 1784778178125889536
author Kurmann, Christoph C.
Mujanovic, Adnan
Piechowiak, Eike I.
Dobrocky, Tomas
Zibold, Felix
Beyeler, Morin
Vynckier, Jan
Seiffge, David
Meinel, Thomas R.
Mordasini, Pasquale
Arnold, Marcel
Fischer, Urs
Gralla, Jan
Kaesmacher, Johannes
author_facet Kurmann, Christoph C.
Mujanovic, Adnan
Piechowiak, Eike I.
Dobrocky, Tomas
Zibold, Felix
Beyeler, Morin
Vynckier, Jan
Seiffge, David
Meinel, Thomas R.
Mordasini, Pasquale
Arnold, Marcel
Fischer, Urs
Gralla, Jan
Kaesmacher, Johannes
author_sort Kurmann, Christoph C.
collection PubMed
description PURPOSE: Incomplete reperfusion after mechanical thrombectomy (MT) is associated with a poor outcome. Rescue therapy would potentially benefit some patients with an expanded treatment in cerebral ischemia score (eTICI) 2b50/2b67 reperfusion but also harbors increased risks. The relative benefits of eTICI 2c/3 over eTICI 2b50/67 in clinically important subpopulations were analyzed. METHODS: Retrospective analysis of our institutional database for all patients with occlusion of the intracranial internal carotid artery (ICA) or the M1/M2 segment undergoing MT and final reperfusion of ≥eTICI 2b50 (903 patients). The heterogeneity in subgroups of different time metrics, age, National Institutes of Health Stroke Scale (NIHSS), number of retrieval attempts, Alberta Stroke Programme Early CT Score (ASPECTS) and site of occlusion using interaction terms (p(i)) was analyzed. RESULTS: The presence of eTICI 2c/3 was associated with better outcomes in most subgroups. Time metrics showed no interaction of eTICI 2c/3 over eTICI 2b50/2b67 and clinical outcomes (onset to reperfusion p(i) = 0.77, puncture to reperfusion p(i) = 0.65, onset to puncture p(i) = 0.63). An eTICI 2c/3 had less consistent association with mRS ≤2 in older patients (>82 years, p(i) = 0.038) and patients with either lower NIHSS (≤9) or very high NIHSS (>19, p(i) = 0.01). Regarding occlusion sites, the beneficial effect of eTICI 2c/3 was absent for occlusions in the M2 segments (aOR 0.73, 95% confidence interval [CI] 0.33–1.59, p(i) = 0.018). CONCLUSION: Beneficial effect of eTICI 2c/3 over eTICI 2b50/2b67 only decreased in older patients, M2-occlusions and patients with either low or very high NIHSS. Improving eTICI 2b50/2b67 to eTICI 2c/3 in those subgroups may be more often futile. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00062-021-01131-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-9424153
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-94241532022-08-31 Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67: Are there Patients who are less Likely to Benefit? Kurmann, Christoph C. Mujanovic, Adnan Piechowiak, Eike I. Dobrocky, Tomas Zibold, Felix Beyeler, Morin Vynckier, Jan Seiffge, David Meinel, Thomas R. Mordasini, Pasquale Arnold, Marcel Fischer, Urs Gralla, Jan Kaesmacher, Johannes Clin Neuroradiol Original Article PURPOSE: Incomplete reperfusion after mechanical thrombectomy (MT) is associated with a poor outcome. Rescue therapy would potentially benefit some patients with an expanded treatment in cerebral ischemia score (eTICI) 2b50/2b67 reperfusion but also harbors increased risks. The relative benefits of eTICI 2c/3 over eTICI 2b50/67 in clinically important subpopulations were analyzed. METHODS: Retrospective analysis of our institutional database for all patients with occlusion of the intracranial internal carotid artery (ICA) or the M1/M2 segment undergoing MT and final reperfusion of ≥eTICI 2b50 (903 patients). The heterogeneity in subgroups of different time metrics, age, National Institutes of Health Stroke Scale (NIHSS), number of retrieval attempts, Alberta Stroke Programme Early CT Score (ASPECTS) and site of occlusion using interaction terms (p(i)) was analyzed. RESULTS: The presence of eTICI 2c/3 was associated with better outcomes in most subgroups. Time metrics showed no interaction of eTICI 2c/3 over eTICI 2b50/2b67 and clinical outcomes (onset to reperfusion p(i) = 0.77, puncture to reperfusion p(i) = 0.65, onset to puncture p(i) = 0.63). An eTICI 2c/3 had less consistent association with mRS ≤2 in older patients (>82 years, p(i) = 0.038) and patients with either lower NIHSS (≤9) or very high NIHSS (>19, p(i) = 0.01). Regarding occlusion sites, the beneficial effect of eTICI 2c/3 was absent for occlusions in the M2 segments (aOR 0.73, 95% confidence interval [CI] 0.33–1.59, p(i) = 0.018). CONCLUSION: Beneficial effect of eTICI 2c/3 over eTICI 2b50/2b67 only decreased in older patients, M2-occlusions and patients with either low or very high NIHSS. Improving eTICI 2b50/2b67 to eTICI 2c/3 in those subgroups may be more often futile. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00062-021-01131-0) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2022-01-06 2022 /pmc/articles/PMC9424153/ /pubmed/34989817 http://dx.doi.org/10.1007/s00062-021-01131-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Kurmann, Christoph C.
Mujanovic, Adnan
Piechowiak, Eike I.
Dobrocky, Tomas
Zibold, Felix
Beyeler, Morin
Vynckier, Jan
Seiffge, David
Meinel, Thomas R.
Mordasini, Pasquale
Arnold, Marcel
Fischer, Urs
Gralla, Jan
Kaesmacher, Johannes
Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67: Are there Patients who are less Likely to Benefit?
title Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67: Are there Patients who are less Likely to Benefit?
title_full Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67: Are there Patients who are less Likely to Benefit?
title_fullStr Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67: Are there Patients who are less Likely to Benefit?
title_full_unstemmed Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67: Are there Patients who are less Likely to Benefit?
title_short Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67: Are there Patients who are less Likely to Benefit?
title_sort heterogeneity of the relative benefits of tici 2c/3 over tici 2b50/2b67: are there patients who are less likely to benefit?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424153/
https://www.ncbi.nlm.nih.gov/pubmed/34989817
http://dx.doi.org/10.1007/s00062-021-01131-0
work_keys_str_mv AT kurmannchristophc heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit
AT mujanovicadnan heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit
AT piechowiakeikei heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit
AT dobrockytomas heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit
AT ziboldfelix heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit
AT beyelermorin heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit
AT vynckierjan heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit
AT seiffgedavid heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit
AT meinelthomasr heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit
AT mordasinipasquale heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit
AT arnoldmarcel heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit
AT fischerurs heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit
AT grallajan heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit
AT kaesmacherjohannes heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit